Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Gene Therapy Promise | Neurogene's NGN-401 shows potential in treating Rett syndrome, a rare neurological disorder, with encouraging safety data and functional activity in preclinical studies |
Market Opportunity | Rett syndrome treatment market estimated at $2.5 billion, with Neurogene's NGN-401 positioned for potential 60% market share in a projected duopoly |
Financial Landscape | Despite negative EPS forecasts through 2025, Neurogene maintains a healthy cash position. Analysts set a $65 price target, reflecting confidence in future growth |
EXACT Platform Edge | Explore Neurogene's EXACT technology, a self-regulatory platform with potential to expand gene therapy applications beyond Rett syndrome to other genetic disorders |
Metrics to compare | NGNE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNGNEPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.8x | −1.1x | −0.5x | |
PEG Ratio | 0.01 | 0.00 | 0.00 | |
Price/Book | 1.1x | 0.8x | 2.6x | |
Price / LTM Sales | 333.7x | 9.7x | 3.3x | |
Upside (Analyst Target) | 112.9% | 243.8% | 43.4% | |
Fair Value Upside | Unlock | 49.5% | 7.1% | Unlock |